Comprehensive Stock Comparison
Compare BridgeBio Pharma, Inc. (BBIO) vs BioMarin Pharmaceutical Inc. (BMRN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | BBIO | 126.3% revenue growth vs BMRN's 12.9% |
| Quality / Margins | BMRN | 10.8% net margin vs BBIO's -145.3% |
| Stability / Safety | BMRN | Beta 0.74 vs BBIO's 1.04 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | BBIO | +90.5% vs BMRN's -13.3% |
| Efficiency (ROA) | BMRN | 4.6% ROA vs BBIO's -77.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
BridgeBio Pharma is a biopharmaceutical company focused on discovering and developing precision medicines for genetic diseases. It generates revenue primarily through drug development partnerships and potential future product sales — though currently in pre-revenue stage with multiple programs in clinical trials. The company's key advantage is its efficient hub-and-spoke operating model that allows rapid development of targeted therapies for rare genetic conditions.
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing therapies for rare genetic diseases. It generates revenue primarily from sales of its orphan drug portfolio — including Voxzogo, Vimizim, and Palynziq — with additional income from licensing and royalties. The company's moat lies in its deep expertise in rare disease biology and its established commercial infrastructure for ultra-orphan drugs, which creates high barriers to entry.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
BMRN leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). BBIO leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
BMRN is the larger business by revenue, generating $3.2B annually — 6.4x BBIO's $502M. BMRN is the more profitable business, keeping 10.8% of every revenue dollar as net income compared to BBIO's -145.3%. On growth, BBIO holds the edge at +25.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | BBIOBridgeBio Pharma,… | BMRNBioMarin Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $502M | $3.2B |
| EBITDAEarnings before interest/tax | -$560M | $613M |
| Net IncomeAfter-tax profit | -$729M | $349M |
| Free Cash FlowCash after capex | -$458M | $725M |
| Gross MarginGross profit ÷ Revenue | +94.4% | +77.1% |
| Operating MarginEBIT ÷ Revenue | -113.3% | +16.6% |
| Net MarginNet income ÷ Revenue | -145.3% | +10.8% |
| FCF MarginFCF ÷ Revenue | -91.1% | +22.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +25.2% | +17.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +28.6% | -134.4% |
Valuation Metrics
| Metric | BBIOBridgeBio Pharma,… | BMRNBioMarin Pharmace… |
|---|---|---|
| Market CapShares × price | $12.9B | $11.9B |
| Enterprise ValueMkt cap + debt − cash | $12.4B | $11.1B |
| Trailing P/EPrice ÷ TTM EPS | -17.54x | 34.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 15.45x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 18.18x |
| Price / SalesMarket cap ÷ Revenue | 25.79x | 3.68x |
| Price / BookPrice ÷ Book value/share | — | 2.00x |
| Price / FCFMarket cap ÷ FCF | — | 16.36x |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), BMRN scores 5/9 vs BBIO's 3/9, reflecting solid financial health.
| Metric | BBIOBridgeBio Pharma,… | BMRNBioMarin Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | — | +5.7% |
| ROA (TTM)Return on assets | -77.9% | +4.6% |
| ROICReturn on invested capital | — | +7.4% |
| ROCEReturn on capital employed | -80.6% | +7.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | — | 0.10x |
| Net DebtTotal debt minus cash | -$560M | -$715M |
| Cash & Equiv.Liquid assets | $570M | $1.3B |
| Total DebtShort + long-term debt | $10M | $597M |
| Interest CoverageEBIT ÷ Interest expense | -6.10x | 48.95x |
Total Returns (with DRIP)
A $10,000 investment in BBIO five years ago would be worth $9,245 today (with dividends reinvested), compared to $7,797 for BMRN. Over the past 12 months, BBIO leads with a +90.5% total return vs BMRN's -13.3%. The 3-year compound annual growth rate (CAGR) favors BBIO at 79.9% vs BMRN's -14.7% — a key indicator of consistent wealth creation.
| Metric | BBIOBridgeBio Pharma,… | BMRNBioMarin Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | -15.0% | +3.8% |
| 1-Year ReturnPast 12 months | +90.5% | -13.3% |
| 3-Year ReturnCumulative with dividends | +482.1% | -38.0% |
| 5-Year ReturnCumulative with dividends | -7.6% | -22.0% |
| 10-Year ReturnCumulative with dividends | +141.3% | -24.6% |
| CAGR (3Y)Annualised 3-year return | +79.9% | -14.7% |
Risk & Volatility
BMRN is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than BBIO's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BMRN currently trades 84.0% from its 52-week high vs BBIO's 78.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BBIOBridgeBio Pharma,… | BMRNBioMarin Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.04x | 0.74x |
| 52-Week HighHighest price in past year | $84.94 | $73.51 |
| 52-Week LowLowest price in past year | $28.33 | $50.76 |
| % of 52W HighCurrent price vs 52-week peak | +78.3% | +84.0% |
| RSI (14)Momentum oscillator 0–100 | 39.0 | 56.6 |
| Avg Volume (50D)Average daily shares traded | 2.5M | 1.9M |
Analyst Outlook
Wall Street rates BBIO as "Buy" and BMRN as "Buy". Consensus price targets imply 48.8% upside for BBIO (target: $99) vs 32.8% for BMRN (target: $82).
| Metric | BBIOBridgeBio Pharma,… | BMRNBioMarin Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $98.92 | $82.00 |
| # AnalystsCovering analysts | 26 | 40 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.4% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| BridgeBio Pharma, I… (BBIO) | 100 | 242.91 | +142.9% |
| BioMarin Pharmaceut… (BMRN) | 100 | 61.39 | -38.6% |
BridgeBio Pharma, I… (BBIO) returned -8% over 5 years vs BioMarin Pharmaceut… (BMRN)'s -22%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BridgeBio Pharma, I… (BBIO) | $0.00 | $502M | — |
| BioMarin Pharmaceut… (BMRN) | $1.1B | $0.00 | -100.0% |
BioMarin Pharmaceutical Inc.'s revenue grew from $1.1B (2016) to $0M (2025) — a -100.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BridgeBio Pharma, I… (BBIO) | -6.4% | -145.3% | -2162.2% |
| BioMarin Pharmaceut… (BMRN) | -56.4% | 15.0% | +126.5% |
Chart 4P/E Ratio History — 5 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| BioMarin Pharmaceut… (BMRN) | 19.4 | 424.5 | +2088.1% |
BioMarin Pharmaceutical Inc. has traded in a 19x–425x P/E range over 5 years; current trailing P/E is ~34x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BridgeBio Pharma, I… (BBIO) | -0.33 | -3.79 | -1048.5% |
| BioMarin Pharmaceut… (BMRN) | -3.79 | 0.14 | +103.7% |
BioMarin Pharmaceutical Inc.'s EPS grew from $-3.79 (2016) to $0.14 (2025).
Chart 6Free Cash Flow — 5 Years
BridgeBio Pharma, Inc. generated $-447M FCF in 2025 (+18% vs 2021). BioMarin Pharmaceutical Inc. generated $725M FCF in 2025 (+291% vs 2021).
BBIO vs BMRN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BBIO or BMRN a better buy right now?
BioMarin Pharmaceutical Inc. (BMRN) offers the better valuation at 34.3x trailing P/E (15.4x forward), making it the more compelling value choice. Analysts rate BridgeBio Pharma, Inc. (BBIO) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BBIO or BMRN?
Over the past 5 years, BridgeBio Pharma, Inc. (BBIO) delivered a total return of -7.6%, compared to -22.0% for BioMarin Pharmaceutical Inc. (BMRN). A $10,000 investment in BBIO five years ago would be worth approximately $9K today (assuming dividends reinvested). Over 10 years, the gap is even starker: BBIO returned +141.3% versus BMRN's -24.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BBIO or BMRN?
By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc. (BMRN) is the lower-risk stock at 0.74β versus BridgeBio Pharma, Inc.'s 1.04β — meaning BBIO is approximately 39% more volatile than BMRN relative to the S&P 500.
04Which has better profit margins — BBIO or BMRN?
BioMarin Pharmaceutical Inc. (BMRN) is the more profitable company, earning 10.8% net margin versus -145.3% for BridgeBio Pharma, Inc. — meaning it keeps 10.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMRN leads at 16.6% versus -113.3% for BBIO. At the gross margin level — before operating expenses — BBIO leads at 94.4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is BBIO or BMRN more undervalued right now?
Analyst consensus price targets imply the most upside for BBIO: 48.8% to $98.92.
06Which pays a better dividend — BBIO or BMRN?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BBIO or BMRN better for a retirement portfolio?
For long-horizon retirement investors, BioMarin Pharmaceutical Inc. (BMRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.74)). Both have compounded well over 10 years (BMRN: -24.6%, BBIO: +141.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BBIO and BMRN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.